Wire · regulatory
South Africa revises rules around customisation of weight-loss drugs
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 October 2026 · Fusion42 review
South Africa is updating regulations on compounding medicines, particularly targeting the customisation of GLP-1 weight-loss drugs, to prevent pharmacies from acting as small-scale manufacturers and to reduce the risk of counterfeit medicines.
This Wire brief sits within Fusion42's coverage of Health, and 3 sources have reported it between 14 Oct 2026 and 15 Oct 2026.
◆ ◆ The Wire takeaway
You face tighter rules on customising weight-loss drugs in South Africa, with new limits on pharmacy compounding that could close informal channels and shift demand back to branded suppliers. Adjust your compliance and supply strategies to avoid regulatory penalties and counterfeiting risks.
◆ Coverage
3 sources · first reported 14 Oct 2026 · latest 15 Oct 2026
◆ Related on Wire
◆ Topics